ETF Building Blocks ChannelConsolidation Could Come Calling for Biotech in 2022By Tom LydonJanuary 5, 2022
ETF Building Blocks ChannelMemeification of Biotech Stocks Shines Light on This ETFBy Tom LydonNovember 24, 2021
ETF Building Blocks ChannelBiotech Ready to Participate in Healthcare BullishnessBy Tom LydonOctober 29, 2021
ETF Building Blocks ChannelDrug Price Debate May Not Hinder Biotech ETFs After AllBy Tom LydonSeptember 16, 2021
ETF Building Blocks ChannelBiotech Stocks Have Colds, but They Can HealBy Tom LydonSeptember 13, 2021
Alternatives ChannelDuff & Phelps Introduces Actively Managed Clean Energy ETF, ‘VCLN’By Aaron NeuwirthAugust 4, 2021
ETF Building Blocks ChannelWill the Biotech Space Consolidate in the Back Half of the Year?By Tom LydonJuly 14, 2021
ETF Building Blocks ChannelPost-Pandemic Healthcare Could Feature More Biotech M&ABy Tom LydonJune 10, 2021
ETF Building Blocks ChannelAs Biotech Consolidation Heats up, ‘SBIO’ Could Be a WinnerBy Tom LydonMay 24, 2021
Alternatives ChannelActive Municipal Bond ETFs: A Rare, Overlooked Asset ClassBy Tom LydonMay 24, 2021
Alternatives ChannelImpact and Income: Are Utilities the Next Impact Investments?By Tom LydonApril 20, 2021
New ETFsNewfleet and Virtus ETFs Launch Securitized Debt ETF, ‘VABS’By Aaron NeuwirthFebruary 10, 2021
ETF Building Blocks ChannelCapture Medical Breakthroughs and Big Acquisition Bucks with ‘SBIO’By Tom LydonFebruary 10, 2021
ETF Building Blocks ChannelALPS ‘SBIO’ ETF: Trial Progress Meets Investing SuccessBy Tom LydonJanuary 25, 2021
